Literature DB >> 22920631

Innate immunity in the pathogenesis of cholangiopathy: a recent update.

Kenichi Harada1, Yasuni Nakanuma.   

Abstract

Biliary innate immunity is involved in the pathogenesis of cholangiopathies in patients with various biliary diseases. Biliary epithelial cells possess an innate immune system consisting of the Toll-like receptor (TLR) family and recognize pathogen-associated molecular patterns (PAMPs). Recently, regulatory mechanisms by intracellular negative regulators including peroxisome proliferator-activated receptor-γ and micro-RNA have been clarified. In primary biliary cirrhosis (PBC) and primary sclerosing cholangitis, dysregulated biliary innate immunity, namely hyper-responsiveness to PAMPs, is associated with the histopathogenesis of cholangiopathy. Moreover, biliary epithelial cells produce monocyte chemotactic protein-1 (MCP-1/CCL2) as a result of the innate immune response and bile ductules play a role in hepatic fibrosis caused by hepatic stellate cells (HSCs). Also, biliary innate immune responses induce the production of two chemokines, fractalkine and macrophage inflammatory protein-3α (MIP-3α), causing the migration of inflammatory cells and a population of antigen-presenting cell found in epithelium, Langerhans cell, and involve chronic cholangitis associated with biliary epithelium-specific innate and acquired immunity in PBC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22920631     DOI: 10.2174/187152812803589976

Source DB:  PubMed          Journal:  Inflamm Allergy Drug Targets        ISSN: 1871-5281


  3 in total

1.  Integrated pharmacokinetic, pharmacodynamic and immunogenicity profiling of an anti-CCL21 monoclonal antibody in cynomolgus monkeys.

Authors:  S Dudal; K Subramanian; T Flandre; W S Law; P J Lowe; A Skerjanec; J-C Genin; M Duval; A Piequet; A Cordier; G Jarai; G Van Heeke; S Taplin; C Krantz; S Jones; A P Warren; F R Brennan; J Sims; P Lloyd
Journal:  MAbs       Date:  2015       Impact factor: 5.857

Review 2.  Epithelial Anion Transport as Modulator of Chemokine Signaling.

Authors:  Andrea Schnúr; Péter Hegyi; Simon Rousseau; Gergely L Lukacs; Guido Veit
Journal:  Mediators Inflamm       Date:  2016-06-12       Impact factor: 4.711

3.  Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study.

Authors:  Bertus Eksteen; Christopher L Bowlus; Aldo J Montano-Loza; Eric Lefebvre; Laurent Fischer; Pamela Vig; Eduardo Bruno Martins; Jawad Ahmad; Kidist K Yimam; Paul J Pockros; Jordan J Feld; Gerald Minuk; Cynthia Levy
Journal:  Hepatol Commun       Date:  2020-12-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.